BJ-1108, a 6-Amino-2,4,5-trimethylpyridin-3-ol analogue, ameliorates DSS-induced colitis in miceopen access
- Authors
- Cho, H. J.; Kim, E. S.; Lee, H.; Kim, J. -A.; Jeong, B. -S.; Nam, T. -g.; Lee, Y. -J.
- Issue Date
- Feb-2018
- Publisher
- OXFORD UNIV PRESS
- Citation
- JOURNAL OF CROHNS & COLITIS, v.12, pp.S142 - S143
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CROHNS & COLITIS
- Volume
- 12
- Start Page
- S142
- End Page
- S143
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/6809
- DOI
- 10.1093/ecco-jcc/jjx180.224
- ISSN
- 1873-9946
- Abstract
- Background
Inflammatory bowel disease (IBD) is characterised by a chronic inflammation of gastrointestinal tract with unknown aetiology. Oxidative stress is one of contributing factors associated with the disease severity of IBD, and currently has been implicated as a therapeutic target. Previous studies showed that BJ-1108, a derivative of 6-amino-2,4,5-trimethylpyridin-3-ol, significantly inhibited reactive oxygen species (ROS) generation resulting in suppression of tumour growth in vitro. We therefore investigated the effects of BJ-1108 on dextran sulfate sodium (DSS)-induced experimental colitis in mice.
Methods
DSS-induced colitis was made by two cycles of DSS (2%) administration followed by 7-day water administration. The effect of BJ-1108 was also evaluated in vitro using Caco-2 cells.
Results
DSS-treated mice exhibited severe colitis, whereas mice administrated BJ-1108 improved the disease severity indicated by body weight, histological scores, spleen weight, T cell and macrophage infiltrates. BJ-1108 administration also inhibited colonic expression of NF-kB p65 and IL-1β in vivo. In addition, BJ-1108 treated mice had the enhanced epithelial barrier function indicated by in vivo intestinal permeability and the expression of tight junction proteins such as ZO-1, occludin, claudin-1 and claudin-3 in DSS-induced colitis model. Next, we used in vitro Caco-2 cells to confirm the effects of BJ-1108 on ROS generation and barrier function. As expected, BJ-1108 treated Caco-2 cells significantly ameliorated the cytokine-induced ROS generation in dose-dependent manner. In addition, BJ-1108 remarkably recovered in vitro injured-barrier functions assessed by transepithelial electrical resistance and tight junction protein expression in dose-dependent manner. Finally, we founded that BJ-1108 suppressed NF-kB p65 and PI3K/AKT pathway, and slightly p38/JNK pathway in time-dependent manner.
Conclusions
Collectively, these results provided that BJ-1108 had a therapeutic potential for IBD through reduction of ROS generation and inhibition of NF-kB and PI3K/AKT pathway.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/6809)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.